Drug Profile
Research programme: factor Xa inhibitors - Astellas Pharma
Alternative Names: Factor Xa inhibitors research programme - Astellas Pharma; YM 96765Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 15 Sep 2004 Preclinical trials in Thrombosis in Japan (unspecified route)